DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis

Information source: Ruijin Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pancreatitis,Acute Necrotizing

Intervention: cefoperazone + metronidazole (Drug); oral care by chlorhexidine gluconate (Procedure); enteral nutrition (Procedure); Somatostatin (Drug); Meropenem (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Erzhen Chen

Official(s) and/or principal investigator(s):
Er-Zhen Chen, M.D. & Ph.D., Study Chair, Affiliation: Ruijin Hospital
En-Qiang Mao, M.D. & Ph.D., Study Director, Affiliation: Ruijin Hospital
Zhi-Tao Yang, M.D. & Ph.D., Principal Investigator, Affiliation: Ruijin Hospital

Overall contact:
Erzhen Chen, M.D, Phone: 86-13901753478

Summary

Strategy of antibiotic therapy in SAP,De-escalate (cefoperazone+metronidazole) or Escalate (meropenem) therapy,which one is better.

Clinical Details

Official title: Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: pancreatic or peripancreatic infection

Secondary outcome:

cost of management of SAP

Microbiology resistance

Detailed description: SAP is a serious and life-threatening disease and requires intensive and aggressive management of multiple organ failure and severe infectious complications that can develop in these patients. The most common cause of death in patients suffering from severe acute pancreatitis (SAP) is the infection of pancreatic necrosis by enteric bacteria with mortality rates of 30% (range 14- 62%),spurring the discussion of whether or not prophylactic antibiotic administration could be a beneficial approach. Pancreatic infections are more often monomicrobial, especially E. coli in the two first weeks (100% and 62. 5%) of onset, with a shift from gram-negative to gram-positive as the pancreatitis progressed. In order to evaluate the benefit of prophylactic antibiotic application, a number of randomized controlled clinical trials have been published over the past 15 years. Since the results were conflicting and most studies were of low methodological quality and/or statistically underpowered, meta-analyses have been performed to assess this important issue. However, their results ranged from absolutely no effect of antibiotic prophylaxis to positive effects regarding mortality, the incidence of infected pancreatic necrosis and the incidence of extra pancreatic infections. In order to provide reliable evidence of the effect of antibiotherapy strategy in SAP, we performed a prospective randomized multicenter clinical trial.

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- severe Acute Pancreatitis according to Atlanta criteria revisited in 2012

Exclusion Criteria:

- concurrent sepsis or (peri)pancreatic infection caused by a second disease

- patients with chronic organ failure (chronic renal failure needs kidney replacement,

chronic heart failure, decompensate hepatic cirrhosis, chronic obstructive pulmonary disease)

- recurrent or endoscopic retrograde cholangiopancreatography (ERCP), or traumatic or

operative pancreatitis

- pregnancy, malignancy or immunodeficiency

- a history of allergy to meropenem, cefoperazone and metronidazole

- a history of antibiotic administration within 48 h prior to enrollment

- possible death within 48 h after enrollment

Locations and Contacts

Erzhen Chen, M.D, Phone: 86-13901753478

Depatrment of EICU,Ruijin Hospital, Shanghai, Shanghai 200025, China; Recruiting
Erzhen Chen, M.D, Phone: 86-13901753478
Enqiang , Mao, Phone: 86-13501747906
Zhitao Yang, M.D, Sub-Investigator
Additional Information

Starting date: July 2012
Last updated: November 18, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017